Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Accounts Payables: 2022-2025

Historic Accounts Payables for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $10.1 million.

  • NewAmsterdam Pharma Co N.V's Accounts Payables fell 4.56% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 4.56%. This contributed to the annual value of $13.6 million for FY2024, which is 19.59% down from last year.
  • As of Q3 2025, NewAmsterdam Pharma Co N.V's Accounts Payables stood at $10.1 million, which was up 6.74% from $9.5 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year Accounts Payables high stood at $16.9 million for Q4 2023, and its period low was $20,854 during Q2 2023.
  • Moreover, its 3-year median value for Accounts Payables was $10.1 million (2025), whereas its average is $9.9 million.
  • Over the last 5 years, NewAmsterdam Pharma Co N.V's Accounts Payables had its largest YoY gain of 48,782.71% in 2024, and its largest YoY loss of 19.59% in 2024.
  • Over the past 4 years, NewAmsterdam Pharma Co N.V's Accounts Payables (Quarterly) stood at $11.9 million in 2022, then surged by 42.77% to $16.9 million in 2023, then fell by 19.59% to $13.6 million in 2024, then fell by 4.56% to $10.1 million in 2025.
  • Its last three reported values are $10.1 million in Q3 2025, $9.5 million for Q2 2025, and $8.0 million during Q1 2025.